Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:10 pm Sale | 2024-12-31 | 13G | Celularity Inc. CELU | BRISTOL MYERS SQUIBB CO BMY | 426,372 1.900% | -768,955 (-64.33%) | Filing History |
| 2025-02-14 4:10 pm Sale | 2024-12-31 | 13G | Compugen Ltd. CGEN | BRISTOL MYERS SQUIBB CO BMY | 1,840,136 2.060% | -2,916,922 (-61.32%) | Filing History |
| 2025-02-14 4:10 pm Sale | 2024-12-31 | 13G | Q32 Bio Inc. QTTB | BRISTOL MYERS SQUIBB CO BMY | 200,244 1.640% | -558,901 (-73.62%) | Filing History |
| 2024-11-13 4:05 pm Unchanged | 2024-09-30 | 13G | Avidity Biosciences, Inc. RNA | BRISTOL MYERS SQUIBB CO BMY | 5,075,304 4.300% | 0 (Unchanged) | Filing History |
| 2024-11-13 4:05 pm Unchanged | 2024-09-30 | 13G | uniQure N.V. QURE | BRISTOL MYERS SQUIBB CO BMY | 2,388,108 4.900% | 0 (Unchanged) | Filing History |
| 2024-11-13 4:05 pm Unchanged | 2024-09-30 | 13G | Ikena Oncology, Inc. IKNA | BRISTOL MYERS SQUIBB CO BMY | 2,133,142 4.400% | 0 (Unchanged) | Filing History |
| 2024-11-13 4:05 pm Purchase | 2024-03-25 | 13G | Q32 Bio Inc. QTTB | BRISTOL MYERS SQUIBB CO BMY | 759,145 6.230% | 759,145 (New Position) | Filing History |
| 2024-10-04 4:20 pm Purchase | 2023-09-30 | 13G | Prime Medicine, Inc. PRME | BRISTOL MYERS SQUIBB CO BMY | 11,006,163 8.400% | 11,006,163 (New Position) | Filing History |
| 2024-02-13 5:00 pm Sale | 2023-12-29 | 13G | Bristol-Myers Squibb Company BMY | VANGUARD GROUP INC | 198,155,594 9.740% | -4,772,026 (-2.35%) | Filing History |
| 2024-01-25 4:59 pm Sale | 2023-12-31 | 13G | Bristol-Myers Squibb Company BMY | BlackRock Inc. BLK | 168,098,227 8.300% | -4,622,150 (-2.68%) | Filing History |
| 2023-12-04 4:13 pm Purchase | 2023-11-27 | 13G | Avidity Biosciences, Inc. RNA | BRISTOL MYERS SQUIBB CO BMY | 5,075,304 6.400% | 5,075,304 (New Position) | Filing History |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | Bristol-Myers Squibb Company BMY | VANGUARD GROUP INC | 202,927,620 9.540% | 3,093,137 (+1.55%) | Filing History |
| 2023-02-07 2:10 pm Purchase | 2022-12-31 | 13G | Bristol-Myers Squibb Company BMY | BlackRock Inc. BLK | 172,720,377 8.100% | 3,493,671 (+2.06%) | Filing History |
| 2022-02-09 3:33 pm Purchase | 2021-12-31 | 13G | Bristol-Myers Squibb Company BMY | VANGUARD GROUP INC | 199,834,483 9.000% | 494,025 (+0.25%) | Filing History |
| 2022-01-31 5:59 pm Sale | 2021-12-31 | 13G | Bristol-Myers Squibb Company BMY | BlackRock Inc. BLK | 169,226,706 7.600% | -3,238,098 (-1.88%) | Filing History |
| 2021-11-19 4:15 pm Purchase | 2021-11-10 | 13G | Compugen Ltd. CGEN | BRISTOL MYERS SQUIBB CO BMY | 4,757,058 5.500% | 4,757,058 (New Position) | Filing History |
| 2021-07-26 5:10 pm Purchase | 2021-07-16 | 13G | Celularity Inc. CELU | BRISTOL MYERS SQUIBB CO BMY | 1,195,327 9.900% | 1,195,327 (New Position) | Filing History |
| 2021-04-05 5:28 pm Purchase | 2020-12-31 | 13G | Sutro Biopharma, Inc. STRO | BRISTOL MYERS SQUIBB CO BMY | 1,726,197 3.800% | 1,726,197 (New Position) | Filing History |
| 2021-04-05 5:27 pm Purchase | 2019-11-20 | 13G | IDEAYA Biosciences, Inc. IDYA | BRISTOL MYERS SQUIBB CO BMY | 1,633,254 5.100% | 1,633,254 (New Position) | Filing History |
| 2021-04-05 5:26 pm Unchanged | 2021-04-05 | 13D | Agios Pharmaceuticals, Inc. AGIO | BRISTOL MYERS SQUIBB CO BMY | 0 0.000% | 0 (Unchanged) | Filing History |